BioAtla Inc (NASDAQ:BCAB) shares, rose in value on Friday, July 11, with the stock price down by -0.80% to the previous day’s close as strong demand from buyers drove the stock to $0.38.
Actively observing the price movement in the last trading, the stock closed the session at $0.39, falling within a range of $0.38 and $0.392. The value of beta (5-year monthly) was 0.911. Referring to stock’s 52-week performance, its high was $2.53, and the low was $0.24. On the whole, BCAB has fluctuated by -20.98% over the past month.
With the market capitalization of BioAtla Inc currently standing at about $22.40 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-06.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that BCAB’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of BCAB currently trading nearly -2.76% and -10.10% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 44.13, while the 7-day volatility ratio is showing 5.40% which for the 30-day chart, stands at 9.57%. Furthermore, BioAtla Inc (BCAB)’s beta value is 0.90.
A comparison of BioAtla Inc (BCAB) with its peers suggests the former has fared considerably weaker in the market. BCAB showed an intraday change of -0.80% in last session, and over the past year, it shrunk by -35.13%%.
Data on historical trading for BioAtla Inc (NASDAQ:BCAB) indicates that the trading volumes over the past 10 days have averaged 0.56 and over the past 3 months, they’ve averaged 534.32K. According to company’s latest data on outstanding shares, there are 58.40 million shares outstanding.
Nearly 23.95% of BioAtla Inc’s shares belong to company insiders and institutional investors own 18.51% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 4.12 million shares as on 2025-06-13, resulting in a short ratio of 7.85. According to the data, the short interest in BioAtla Inc (BCAB) stood at 792.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 4.34 million. The stock has fallen by -67.22% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the BCAB stock heading into the next quarter.
